FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burd	en							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BOGER JOSHUA S					VI	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]									all application of the contraction of the contracti	10% Owner (give title Other (specif		ner	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST.					08/	3. Date of Earliest Transaction (Month/Day/Year) 08/22/2012 4. If Amendment, Date of Original Filed (Month/Day/Year)									below)			below)	
(Street) CAMBRIDGE MA 02139					- 4. II -	Amen	amer	it, Date	of Origi	nai Fii	ed (Month/Da		inaiv ne) X						
(City)																			
		Tab	le I - N	on-Deriv	vative	Sec	uriti	es Ac	quire	d, D	isposed o			ally (Owned	l			
1		2. Transaction Date (Month/Day/Yea		Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			Benefici Owned I		es ally Following	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code V		Amount	(A) or (D) Price			Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)	
Common Stock			08/22/2	2012				M		4,000	A	\$15.0	6	636	6,895		D		
Common Stock 08/22/20					2012)12		S ⁽¹⁾		4,000	D	\$54.59	(2)(3) 63		2,895		D		
Common Stock														13	,286 I		I 4	401(k)	
Common Stock											300,0),000		I S	Common Stock neld in rust. ⁽⁴⁾			
		Т	able II								posed of, converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	on Date,	4. Transa Code (8)			6. Date Exerc Expiration Da (Month/Day/Y		ate	7. Title ar Amount of Securities Underlyin Derivative (Instr. 3 a	of s ng e Security	8. Price Derivati Security (Instr. 5			ly [10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares						
Employee Stock Option (right to buy)	\$15.6	08/22/2012			M			4,000	(5)		01/17/2013	Common Stock	4,000		\$0.00	74,951		D	

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Dr.\ Boger's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Open market sales reported on this line occurred at a weighted average price of \$54.59 (range \$54.31 to \$54.95).
- 3. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Common stock held in grantor retained annuity trusts.
- 5. Fully vested.

Remarks:

Valerie L. Andrews, Attorney-

08/23/2012

In-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.